Skip to main content
XBIO logo

Xenetic Biosciences, Inc.

XBIONASDAQHealthcareBiotechnology

$1.85Today:- (-)1Y −50.78%

As of Oct 26, 2026 close

Market cap
$4.24M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.85$4.94
Volume (live)
-
Avg. volume (3M)
118.58K

Xenetic Biosciences (XBIO) Income Statement

Xenetic Biosciences reported revenue of $2.98M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 19.0% from $2.50M a year earlier. Xenetic Biosciences posted a net loss of $2.68M, compared with a net loss of $3.96M a year earlier. Gross margin was 100.0% and operating margin -95.2%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $660.60K, up 12.0% from the same quarter a year earlier.

Xenetic Biosciences Income Statement Analysis

Values in millions USD

Scroll to see more
Xenetic Biosciences, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Mar 2019Dec 2017
Revenue & Gross Profit
Revenue2.982.502.541.711.160.440.020.007.59
Cost of Revenue0.000.000.000.000.000.000.000.020.16
Gross Profit2.982.502.541.711.160.440.02-0.027.43
Operating Expenses
Research & Development3.073.293.494.773.161.734.892.884.06
Selling, General & Administrative2.753.423.563.653.743.404.734.396.94
Operating Expenses5.816.707.068.426.915.1312.907.2811.00
Operating Income-2.83-4.20-4.52-6.72-5.75-4.69-12.89-7.28-3.57
Other Income/Expense
Interest Income0.150.250.360.170.100.130.110.000.02
Interest Expense0.000.000.000.000.000.000.000.020.00
Other Income/Expense0.01-0.010.380.170.100.000.11-0.02-0.03
Income
Income Before Tax-2.68-3.96-4.13-6.55-5.65-13.81-12.78-7.30-3.60
Income Tax Expense0.000.000.000.000.00-2.920.000.020.03
Net Income-2.68-3.96-4.13-6.55-5.65-10.89-12.78-7.30-3.60
Net Income - Continuous Operations-2.68-3.96-4.13-6.55-5.65-10.89-12.78-7.30-3.60
Net Income - Discontinued Operations---------
EBITDA-2.83-4.20-4.13-6.53-5.61-4.69-9.58-7.26-3.57
EBIT-2.83-4.20-4.52-6.72-5.75-4.69---
Depreciation & Amortization0.000.150.000.030.040.000.030.020.02
Earnings Per Share
Basic EPS-2.00-3.00-3.00-4.00-5.00-17.00-56.00-97.00-50.00
Diluted EPS-2.00-3.00-3.00-4.00-5.00-17.00-56.00-97.00-50.00
Basic Shares Outstanding1.701.541.531.421.030.640.290.080.07
Diluted Shares Outstanding1.701.541.531.421.030.640.290.080.07

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xenetic Biosciences Financial Statements

What was Xenetic Biosciences's revenue in fiscal 2025?

Xenetic Biosciences reported revenue of $2.98M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 19.0% from $2.50M a year earlier.

Is Xenetic Biosciences profitable?

No. Xenetic Biosciences reported a net loss of $2.68M in fiscal 2025. In fiscal 2024 it lost $3.96M.

What is Xenetic Biosciences's operating margin?

Xenetic Biosciences's operating income was −$2.83M on revenue of $2.98M in fiscal 2025, an operating margin of -95.2%, compared with -168.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition